SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?


To: Thomas who wrote (205)3/29/2004 10:34:01 AM
From: tuck  Read Replies (1) | Respond to of 671
 
No thoughts beyond the article, no. Meanwhile, a team from the Lawrence Livermore lab comes up with a DNA:RNA hybrid that may trump RNAi:

>>Mol Biotechnol. 2003 Jun;24(2):111-20.

Varying the nucleic acid composition of siRNA molecules dramatically varies the duration and degree of gene silencing.

Lamberton JS, Christian AT.

Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, PO Box 808, L-448, Livermore, CA, 94551, USA.

The utility of short interfering RNA (siRNA) as a means of gene silencing depends on several factors. These include the degree to which a gene can be silenced, the length of time for which the gene remains silenced, the degree of recovery of gene function, and the effects of the silencing process on general cell functions. We hypothesized that changing the nucleic acid composition of the siRNA constructs used for silencing would affect these parameters. With siRNA gene silencing of the glucose-6-phosphate dehydrogenase gene as a baseline, we found that siDNA molecules have an effect that is similar in duration but lesser in degree, whereas hybrid DNA:RNA molecules have an effect that is enormously greater in both duration and degree.<<

In addition to the greater specificity, supposedly this hybrid can be introduced into cells without transfection and could be effective against bacterial genes. More when I find it.

Cheers, Tuck